Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Wedbush Downgrades Allbirds to Neutral, Announces $3 Price Target

Wedbush Downgrades Allbirds to Neutral, Announces $3 Price Target

Wedbush analyst Tom Nikic downgrades Allbirds (NASDAQ:BIRD) from Outperform to Neutral and announces $3 price target.

byBenzinga Newsdesk

March 6, 2023

1 minute read

Wedbush analyst Tom Nikic downgrades Allbirds (NASDAQ:BIRD) from Outperform to Neutral and announces $3 price target.

Oppenheimer Maintains Outperform on Biogen, Lowers Price Target to $310

By Benzinga Newsdesk

February 16, 8:14 AM

Oppenheimer analyst Jay Olson maintains Biogen (NASDAQ:BIIB) with a Outperform and lowers the price target from $320 to $310.

BIIB

America’s Business & Information Services Sector In Focus: Goldman Sachs Keeps Buy On Cintas, Gartner & More

By Nabaparna Bhattacharya

January 9, 4:40 PM

Goldman Sachs analyst George K.

CSGP

Can-Fite To Submit FDA & EMA Registration Plans For Piclidenoson In The Oral Treatment Of Moderate To Severe Psoriasis

By Bill Haddad

July 11, 7:02 AM

Further analysis of Phase III COMFORT™ data show Piclidenoson's superior safety profile and higher patient compliance compared to Otezla® Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CFBI), a

CANF

Sonendo Files For Offering Of Up To 66.4M Shares Of Common Stock By Selling Stockholders

By Michael Horton

November 4, 4:20 PM

-Reuters

SONX

Wedbush Downgrades Allbirds to Neutral, Announces $3 Price Target

Related Posts

Oppenheimer Maintains Outperform on Biogen, Lowers Price Target to $310

America’s Business & Information Services Sector In Focus: Goldman Sachs Keeps Buy On Cintas, Gartner & More

Can-Fite To Submit FDA & EMA Registration Plans For Piclidenoson In The Oral Treatment Of Moderate To Severe Psoriasis

Sonendo Files For Offering Of Up To 66.4M Shares Of Common Stock By Selling Stockholders